

# T2D Outcomes in the Community Setting

THOMAS GRACE, JENNIFER LAYNE, CHRISTIAN HICKS,  
COURTNEY GREEN, TOMAS WALKER



[Access here](#)

Published June 14

## Background

Access to CGM for people with T2D remains limited, especially for those treated in the primary care setting



### Aim

To evaluate long-term change in A1c and CGM metrics in people with less-intensively treated T2D managed in a primary care setting



### Study Design

Prospective, observational study



### Primary Outcomes

- Change in A1c and CGM metrics from baseline to 1 year
- Proportion of participants meeting ADA and HEDIS A1c targets of <7.0% and <8.0%, respectively

## Study Population

 Participants: (N=177)



**T2D**  
(all treatment regimens)



**CGM naïve**





**Uninsured or underinsured adults**

# Results

After One Year, CGM Use Resulted in a **-2.3%** Reduction in HbA1c

HbA1c decreased from 9.4% to 7.1%



**50.8%** increase in the number of participants achieving the ADA target of A1c <7.0%

**66.7%** increase in the number of participants achieving the HEDIS target of A1c <8.0%

CGM Metrics	Baseline	1 year	Change	P-value
GMI (%)	7.5 ± 0.9	7.2 ± 0.8	-0.3 ± 1.0	<0.001
<b>Percent time (%)</b>				
TIR 70-180 mg/dL	60.4 ± 28.2	70.3 ± 23.1	9.9 ± 29.4	<0.001
TITR 70-140 mg/dL	30.4 ± 24.3	39.9 ± 25.7	8.9 ± 27.4	<0.001

## Key Takeaways for Managed Care Decision Makers

- ✓ Self-guided use of Dexcom CGM in people with T2D resulted in clinically significant improvements in A1c and TIR at 12 months, demonstrating that members with less intensively treated T2D can be effectively managed in non-specialist settings.
- ✓ This evidence supports a population-wide approach to coverage and access for all individuals with T2D, regardless of insulin therapy.